A Phase II, Open Label, Randomized Study of Osimertinib (TAgrisso) alone Versus Osimertinib plus Carboplatin/Pemetrexed for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose TUmours Harbour a T790M MutatIon Within the Epidermal Growth Factor Receptor Gene
Latest Information Update: 16 Oct 2024
At a glance
- Drugs Carboplatin (Primary) ; Osimertinib (Primary) ; Pemetrexed (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms TAKUMI Trial
- 01 Apr 2021 Results published in the European Journal of Cancer
- 31 Jan 2021 Primary endpoint (Progression free survival) has not been met, as per Results presented at the 2020 World Conference on Lung Cancer
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer